Last updated on September 2018

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Multiple Myeloma
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Patients diagnosed with relapsed or refractory MM who have received at least one prior line of therapy for MM
  • Age of 18 years (or legal age of consent) or older at time of entry into the study
  • Have documented progression from a prior line of therapy
  • Patients who have initiated treatment with one of the following therapies within 90 days before consent for this study OR in the case where treatment has not yet been initiated, documentation that the treatment strategy was determined before consent for this study must be provided, and treatment must be initiated within 30 days after
    consent

IMiD Proteasome inhibitor Combination novel therapies (an IMiD plus a proteasome inhibitor)*

Exclusion Criteria:

  • Patients who are currently participating in a clinical trial for MM
  • Patients who are not willing or able to provide informed consent
  • Patients who are incarcerated
  • Patients under compulsory detention for treatment of a physical (eg, infectious) or psychiatric illness Patients who are currently receiving treatment for primary cancer other than multiple myeloma

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.